Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00682890 · ClinicalTrials.gov registry record · Phase 4

Combination Metformin and Oral Contraception for Polycystic Ovary Syndrome (PCOS)

A Phase 4 study, sponsored by Virginia Commonwealth University.

Terminated
Registry status
Phase 4
Development phase
28
Enrollment target

NCT00682890 is a Phase 4 study that was terminated before completion, run by Virginia Commonwealth University. The registered enrollment target is 28 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00682890, a Phase 4 study, was terminated before completion, sponsored by Virginia Commonwealth University.

TERMINATED
Registry status
Phase 4
Development phase
28 participants
Enrollment target

Study Summary

The purpose of this research study is to determine if adding Metformin, a drug that reduces insulin resistance, to birth control pills will reduce the risk of developing type 2 diabetes, high blood pressure. high lipid levels and heart disease in women with PCOS

Interventions

  • DRUG placebo
  • DRUG metformin

Trial Details

FieldValue
Enrollment Target 28 participants
Start Date 2005-11
Est. Completion 2010-01
Phase Phase 4

Sponsor

Virginia Commonwealth University

558 total trials

What the Registry Record Tells You About NCT00682890

The ClinicalTrials.gov registry entry for NCT00682890 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Virginia Commonwealth University, which has 558 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.

NCT00682890 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00682890 about?

NCT00682890 is a clinical study titled "Combination Metformin and Oral Contraception for Polycystic Ovary Syndrome (PCOS)". The purpose of this research study is to determine if adding Metformin, a drug that reduces insulin resistance, to birth control pills will reduce the risk of developing type 2 diabetes, high blood pressure. high lipid levels and heart disease in women with PCOS

What is the current status of trial NCT00682890?

This trial is currently terminated. It is a Phase 4 study. The enrollment target is 28 participants. The study started on 2005-11. Estimated completion is 2010-01.

What interventions are being tested in trial NCT00682890?

The interventions under investigation include: placebo (DRUG), metformin (DRUG).

Who is sponsoring clinical trial NCT00682890?

This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.